Researchers now have an opportunity to achieve higher protein yields from transient transfection of suspension CHO cells.
The CHOgro High Yield Expression System is a fully optimized, second-generation protein expression platform featuring the CHOgro Titer Enhancer, which increases the speed and overall yield of the system. Benefits of the new system include:
The CHOgro High Yield Expression System offers a rapid means for developing protein-based biotherapeutics within a single host cell type with titers that exceed all other commercially available transient expression systems. “Transient gene expression has been gaining popularity as a means for producing antibodies and other recombinant proteins in mammalian cells. As the demand for recombinant proteins in drug discovery continues to grow, and with the majority of therapeutic antibodies being produced in CHO cells, we recognized the need for a robust transient expression platform that is fast and reliable,” said Laura Juckem, PhD, Vice President, Scientific Operations. “Traditionally, biopharma companies started their research in 293 cells, and as their projects progressed through the pipeline, they had to take multiple steps backwards to qualify their primary targets in CHO cells.”
“Advances in biomanufacturing are driving rapid change in the drug discovery field,” said Josh Snow, PhD, Director of Business Development & Marketing Strategy. “Our mission with the CHOgro High Yield Expression System is to give scientists an edge by saving a tremendous amount of time, money and effort.” Snow added.
Interested researchers can visit www.mirusbio.com/chogro for comprehensive information, complete experimental data about the CHOgro High Yield Expression System and to request a trial kit.
About Mirus Bio
THE TRANSFECTION EXPERTS – Mirus Bio pioneered scientific breakthroughs in non-viral gene delivery and continues to produce industry-leading transfection reagents. As we expand our expertise in nucleic acid delivery, we give life scientists the most advanced tools for gene expression, biotherapeutic protein production, virus manufacturing and genome editing.
SOURCE: Mirus Bio LLC